FDA Approves Takeda's Entyvio

Wed, 05/21/2014 - 7:59am

Takeda Pharmaceuticals U.S.A., Inc., today announced that the FDA simultaneously approved a new biologic therapy, Entyvio (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

"Entyvio is a new option that works to block important contributors to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn's disease," said Stephen B. Hanauer, M.D., medical director, Digestive Health Center, Northwestern University Feinberg School of Medicine. "The clinical trial program evaluated the efficacy and safety profile of Entyvio and demonstrated that Entyvio has the potential to help adult patients with moderately to severely active UC or CD successfully manage their disease."



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.